Epigenetic regulation in adult stem cells and cancers

Cell and Bioscience

Volumn 3, Issue 1, 2013, Pages

  Tarayrah, Lama ^a   Chen, Xin ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adult stem cell; Cancer; Cancer stem cell; Epigenetics; Germline stem cell; Hair follicle stem cell; Intestinal stem cell

Indexed keywords

EID: 84885150806     PISSN: None     EISSN: 20453701     Source Type: Journal    
DOI: 10.1186/2045-3701-3-41     Document Type: Article

References (123)

1. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705. 10.1016/j.cell.2007.02.005, 17320507.
2. Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009, 10:295-304.
3. Duesberg P, Fabarius A, Hehlmann R. Aneuploidy, the primary cause of the multilateral genomic instability of neoplastic and preneoplastic cells. IUBMB Life 2004, 56:65-81. 10.1080/15216540410001667902, 15085930.
4. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074. 10.1093/jnci/93.14.1062, 11459867.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
6. Boveri T. Concerning the origin of malignant tumours by Theodor Boveri. translated and annotated by Henry Harris. J Cell Sci 2008, 121(Suppl 1):1-84.
7. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010, 10:457-469. 10.1038/nrc2876, 3262678, 20574448.
8. Blair LP, Cao J, Zou MR, Sayegh J, Yan Q. Epigenetic regulation by Lysine Demethylase 5 (KDM5) enzymes in cancer. Cancers (Basel) 2011, 3:1383-1404.
9. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692. 10.1016/j.cell.2007.01.029, 17320506.
10. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
11. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011, 17:330-339.
12. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy?. J Pathol 2011, 223:147-161.
13. Barker N, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611. 10.1038/nature07602, 19092804.
14. Leedham SJ, Thliveris AT, Halberg RB, Newton MA, Wright NA. Gastrointestinal stem cells and cancer: bridging the molecular gap. Stem Cell Rev 2005, 1:233-241. 10.1385/SCR:1:3:233, 17142860.
15. Zhu L, et al. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607. 10.1038/nature07589, 2633030, 19092805.
16. Wang JC, Dick JE. Cancer stem cells: lessons from leukemia. Trends Cell Biol 2005, 15:494-501. 10.1016/j.tcb.2005.07.004, 16084092.
17. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008, 88:459-463. 10.1038/labinvest.2008.14, 3702270, 18379567.
18. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261. 10.1056/NEJMra061808, 16990388.
19. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737. 10.1038/nm0797-730, 9212098.
20. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988. 10.1073/pnas.0530291100, 153034, 12629218.
21. Singh SK, et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
22. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110. 10.1038/nature05372, 17122772.
23. Prince ME, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007, 104:973-978. 10.1073/pnas.0610117104, 1783424, 17210912.
24. Eramo A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514. 10.1038/sj.cdd.4402283, 18049477.
25. Li X, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008, 100:672-679. 10.1093/jnci/djn123, 18445819.
26. Cinalli RM, Rangan P, Lehmann R. Germ cells are forever. Cell 2008, 132:559-562. 10.1016/j.cell.2008.02.003, 18295574.
27. Eun SH, Gan Q, Chen X. Epigenetic regulation of germ cell differentiation. Curr Opin Cell Biol 2010, 22:737-743. 10.1016/j.ceb.2010.09.004, 2993805, 20951019.
28. Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132:598-611. 10.1016/j.cell.2008.01.038, 18295578.
29. Buszczak M, Spradling AC. Searching chromatin for stem cell identity. Cell 2006, 125:233-236. 10.1016/j.cell.2006.04.004, 16630812.
30. Li X, Zhao X. Epigenetic regulation of mammalian stem cells. Stem Cells Dev 2008, 17:1043-1052. 10.1089/scd.2008.0036, 2700624,2700624, 18393635.
31. Sarmento OF, et al. Dynamic alterations of specific histone modifications during early murine development. J Cell Sci 2004, 117:4449-4459. 10.1242/jcs.01328, 15316069.
32. Seligson DB, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005, 435:1262-1266. 10.1038/nature03672, 15988529.
33. Greer EL, et al. Members of the H3K4 trimethylation complex regulate lifespan in a germline-dependent manner in C. elegans. Nature 2010, 466:383-387. 10.1038/nature09195, 3075006, 20555324.
34. Li T, Kelly WG. A role for Set1/MLL-related components in epigenetic regulation of the Caenorhabditis elegans germ line. PLoS Genet 2011, 7:e1001349. 10.1371/journal.pgen.1001349, 3063756, 21455483.
35. Lee KS, Yoon J, Park JS, Kang YK. Drosophila G9a is implicated in germ cell development. Insect Mol Biol 2010, 19:131-139. 10.1111/j.1365-2583.2009.00955.x, 20002223.
36. Wang X, et al. Histone H3K9 trimethylase Eggless controls germline stem cell maintenance and differentiation. PLoS Genet 2011, 7:e1002426. 10.1371/journal.pgen.1002426, 3245301, 22216012.
37. Yang SY, Baxter EM, Van Doren M. Phf7 controls male sex determination in the Drosophila germline. Dev Cell 2012, 22:1041-1051. 10.1016/j.devcel.2012.04.013, 3635078, 22595675.
38. Gan Q, et al. Dynamic regulation of alternative splicing and chromatin structure in Drosophila gonads revealed by RNA-seq. Cell Res 2010, 20:763-783. 10.1038/cr.2010.64, 2919574, 20440302.
39. Eliazer S, Shalaby NA, Buszczak M. Loss of lysine-specific demethylase 1 nonautonomously causes stem cell tumors in the Drosophila ovary. Proc Natl Acad Sci USA 2011, 108:7064-7069. 10.1073/pnas.1015874108, 3084046, 21482791.
40. Tarayrah L, Herz HM, Shilatifard A, Chen X. Histone demethylase dUTX antagonizes JAK-STAT signaling to maintain proper gene expression and architecture of the Drosophila testis niche. Development 2013, 140:1014-1023. 10.1242/dev.089433, 23364332.
41. Xie T, Spradling AC. A niche maintaining germ line stem cells in the Drosophila ovary. Science 2000, 290:328-330. 10.1126/science.290.5490.328, 11030649.
42. Rangan P, et al. piRNA production requires heterochromatin formation in Drosophila. Curr Biol 2011, 21:1373-1379. 10.1016/j.cub.2011.06.057, 3205116, 21820311.
43. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006, 7:715-727.
44. Inaba M, Yamashita YM. Asymmetric stem cell division: precision for robustness. Cell Stem Cell 2012, 11:461-469. 10.1016/j.stem.2012.09.003, 23040475.
45. Tran V, Lim C, Xie J, Chen X. Asymmetric division of Drosophila male germline stem cell shows asymmetric histone distribution. Science 2012, 338:679-682. 10.1126/science.1226028, 3532436, 23118191.
46. Tran V, Feng L, Chen X. Asymmetric distribution of histones during Drosophila male germline stem cell asymmetric divisions. Chromosome Res 2013, 21:255-269. 10.1007/s10577-013-9356-x, 23681658.
47. Smith ER, et al. Drosophila UTX is a histone H3 Lys27 demethylase that colocalizes with the elongating form of RNA polymerase II. Mol Cell Biol 2008, 28:1041-1046. 10.1128/MCB.01504-07, 2223382, 18039863.
48. Mansour AA, et al. The H3K27 demethylase Utx regulates somatic and germ cell epigenetic reprogramming. Nature 2012, 488:409-413. 10.1038/nature11272, 22801502.
49. van Haaften G, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009, 41:521-523. 10.1038/ng.349, 2873835, 19330029.
50. Becker PB, Horz W. ATP-dependent nucleosome remodeling. Annu Rev Biochem 2002, 71:247-273. 10.1146/annurev.biochem.71.110601.135400, 12045097.
51. Bouazoune K, Brehm A. ATP-dependent chromatin remodeling complexes in Drosophila. Chromosome Res 2006, 14:433-449. 10.1007/s10577-006-1067-0, 16821138.
52. Cherry CM, Matunis EL. Epigenetic regulation of stem cell maintenance in the Drosophila testis via the nucleosome-remodeling factor NURF. Cell Stem Cell 2010, 6:557-567. 10.1016/j.stem.2010.04.018, 2897240, 20569693.
53. Xi R, Xie T. Stem cell self-renewal controlled by chromatin remodeling factors. Science 2005, 310:1487-1489. 10.1126/science.1120140, 16322456.
54. Oatley MJ, Racicot KE, Oatley JM. Sertoli cells dictate spermatogonial stem cell niches in the mouse testis. Biol Reprod 2011, 84:639-645. 10.1095/biolreprod.110.087320, 3062034, 21084712.
55. Payne CJ, et al. Sin3a is required by sertoli cells to establish a niche for undifferentiated spermatogonia, germ cell tumors, and spermatid elongation. Stem Cells 2010, 28:1424-1434. 10.1002/stem.464, 3174062, 20572009.
56. Gallagher SJ, et al. Distinct requirements for Sin3a in perinatal male gonocytes and differentiating spermatogonia. Dev Biol 2013, 373:83-94. 10.1016/j.ydbio.2012.10.009, 23085237.
57. Micchelli CA, Perrimon N. Evidence that stem cells reside in the adult Drosophila midgut epithelium. Nature 2006, 439:475-479. 10.1038/nature04371, 16340959.
58. Ohlstein B, Spradling A. The adult Drosophila posterior midgut is maintained by pluripotent stem cells. Nature 2006, 439:470-474. 10.1038/nature04333, 16340960.
59. Ohlstein B, Spradling A. Multipotent Drosophila intestinal stem cells specify daughter cell fates by differential notch signaling. Science 2007, 315:988-992. 10.1126/science.1136606, 17303754.
60. Lin G, Xu N, Xi R. Paracrine Wingless signalling controls self-renewal of Drosophila intestinal stem cells. Nature 2008, 455:1119-1123. 10.1038/nature07329, 18806781.
61. Wang P, Hou SX. Regulation of intestinal stem cells in mammals and Drosophila. J Cell Physiol 2010, 222:33-37. 10.1002/jcp.21928, 19739102.
62. Buszczak M, Paterno S, Spradling AC. Drosophila stem cells share a common requirement for the histone H2B ubiquitin protease scrawny. Science 2009, 323:248-251. 10.1126/science.1165678, 2759887, 19039105.
63. Karpiuk O, et al. The histone H2B monoubiquitination regulatory pathway is required for differentiation of multipotent stem cells. Mol Cell 2012, 46:705-713. 10.1016/j.molcel.2012.05.022, 22681891.
64. Ma Y, Chen Z, Jin Y, Liu W. Identification of a histone acetyltransferase as a novel regulator of Drosophila intestinal stem cells. FEBS Lett 2013, 587:1489-1495. 10.1016/j.febslet.2013.03.013, 23535028.
65. Suganuma T, et al. ATAC is a double histone acetyltransferase complex that stimulates nucleosome sliding. Nat Struct Mol Biol 2008, 15:364-372. 10.1038/nsmb.1397, 18327268.
66. Suganuma T, et al. The ATAC acetyltransferase complex coordinates MAP kinases to regulate JNK target genes. Cell 2010, 142:726-736. 10.1016/j.cell.2010.07.045, 20813260.
67. Nan X, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389. 10.1038/30764, 9620804.
68. Lyko F, Ramsahoye BH, Jaenisch R. DNA methylation in Drosophila melanogaster. Nature 2000, 408:538-540. 10.1038/35046205, 11117732.
69. Lee SH, et al. Regulation of intestinal stem cell proliferation by human methyl-CpG-binding protein-2 in Drosophila. Cell Struct Funct 2011, 36:197-208. 10.1247/csf.11027, 21979236.
70. Morris RJ. Keratinocyte stem cells: targets for cutaneous carcinogens. J Clin Invest 2000, 106:3-8. 10.1172/JCI10508, 314368, 10880041.
71. Slominski A, Paus R. Melanogenesis is coupled to murine anagen: toward new concepts for the role of melanocytes and the regulation of melanogenesis in hair growth. J Invest Dermatol 1993, 101:90S-97S. 10.1111/1523-1747.ep12362991, 8326158.
72. Rabbani P, et al. Coordinated activation of Wnt in epithelial and melanocyte stem cells initiates pigmented hair regeneration. Cell 2011, 145:941-955. 10.1016/j.cell.2011.05.004, 21663796.
73. Nishimura EK, et al. Key roles for transforming growth factor beta in melanocyte stem cell maintenance. Cell Stem Cell 2010, 6:130-140. 10.1016/j.stem.2009.12.010, 3437996, 20144786.
74. Greco V, et al. A two-step mechanism for stem cell activation during hair regeneration. Cell Stem Cell 2009, 4:155-169. 10.1016/j.stem.2008.12.009, 2668200, 19200804.
75. Lien WH, et al. Genome-wide maps of histone modifications unwind in vivo chromatin states of the hair follicle lineage. Cell Stem Cell 2011, 9:219-232. 10.1016/j.stem.2011.07.015, 3166618, 21885018.
76. Ezhkova E, et al. EZH1 and EZH2 cogovern histone H3K27 trimethylation and are essential for hair follicle homeostasis and wound repair. Genes Dev 2011, 25:485-498. 10.1101/gad.2019811, 3049289, 21317239.
77. Pasini D, et al. JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells. Nature 2010, 464:306-310. 10.1038/nature08788, 20075857.
78. Li G, et al. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 2010, 24:368-380. 10.1101/gad.1886410, 2816736, 20123894.
79. Mejetta S, et al. Jarid2 regulates mouse epidermal stem cell activation and differentiation. EMBO J 2011, 30:3635-3646. 10.1038/emboj.2011.265, 3181486, 21811233.
80. Morrison SJ, et al. A genetic determinant that specifically regulates the frequency of hematopoietic stem cells. J Immunol 2002, 168:635-642.
81. Malanchi I, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
82. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983, 301:89-92. 10.1038/301089a0, 6185846.
83. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 1985, 228:187-190. 10.1126/science.2579435, 2579435.
84. Gama-Sosa MA, et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983, 11:6883-6894. 10.1093/nar/11.19.6883, 326421, 6314264.
85. Nakamura N, Takenaga K. Hypomethylation of the metastasis-associated S100A4 gene correlates with gene activation in human colon adenocarcinoma cell lines. Clin Exp Metastasis 1998, 16:471-479.
86. Nishigaki M, et al. Discovery of aberrant expression of R-RAS by cancer-linked DNA hypomethylation in gastric cancer using microarrays. Cancer Res 2005, 65:2115-2124. 10.1158/0008-5472.CAN-04-3340, 15781621.
87. Tahiliani M, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935. 10.1126/science.1170116, 2715015, 19372391.
88. Ito S, et al. Role of Tet proteins in 5mC to 5hmC conversion. ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133. 10.1038/nature09303, 3491567, 20639862.
89. Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol 2010, 11:607-620. 10.1038/nrm2950, 3711520, 20683471.
90. Yang H, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32:663-669. 10.1038/onc.2012.67, 22391558.
91. Lian CG, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146. 10.1016/j.cell.2012.07.033, 3770275, 22980977.
92. Huang H, et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci USA 2013, 110:11994-11999. 10.1073/pnas.1310656110, 23818607.
93. Makishima H, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011, 117:e198-e206. 10.1182/blood-2010-06-292433, 3110035, 21346257.
94. Pui CH, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003, 17:700-706. 10.1038/sj.leu.2402883, 12682627.
95. Mardis ER, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361:1058-1066. 10.1056/NEJMoa0903840, 3201812, 19657110.
96. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843. 10.1038/nature09586, 3003755, 21057493.
97. Hsu CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2012, 2:568-579. 10.1016/j.celrep.2012.08.030, 22999938.
98. Sun M, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA 2013, 110:9920-9925. 10.1073/pnas.1305172110, 23716660.
99. Gonzalez-Zulueta M, et al. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995, 55:4531-4535.
100. Sakai T, et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 1991, 48:880-888. 1683063, 1673287.
101. Avci CB, et al. Promoter hypermethylation-mediated down-regulation of RUNX3 gene in human brain tumors. Ir J Med Sci 2013, [Epub ahead of print].
102. Li ZG, et al. Hypermethylation of two CpG sites upstream of CASP8AP2 promoter influences gene expression and treatment outcome in childhood acute lymphoblastic leukemia. Leuk Res 2013, 2126(13):S0145-S00245.
103. Chedin F. The DNMT3 family of mammalian de novo DNA methyltransferases. Prog Mol Biol Transl Sci 2011, 101:255-285.
104. Chen T, et al. Complete inactivation of DNMT1 leads to mitotic catastrophe in human cancer cells. Nat Genet 2007, 39:391-396. 10.1038/ng1982, 17322882.
105. Bestor TH, Ingram VM. Two DNA methyltransferases from murine erythroleukemia cells: purification, sequence specificity, and mode of interaction with DNA. Proc Natl Acad Sci USA 1983, 80:5559-5563. 10.1073/pnas.80.18.5559, 384297, 6577443.
106. Trowbridge JJ, et al. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012, 26:344-349. 10.1101/gad.184341.111, 3289882, 22345515.
107. Varambally S, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419:624-629. 10.1038/nature01075, 12374981.
108. Kleer CG, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003, 100:11606-11611. 10.1073/pnas.1933744100, 208805, 14500907.
109. Chang CJ, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011, 19:86-100. 10.1016/j.ccr.2010.10.035, 3041516, 21215703.
110. Bao B, et al. Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 2012, 72:335-345. 10.1158/0008-5472.CAN-11-2182, 3792589, 22108826.
111. Crea F, et al. Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Mol Cancer 2011, 10:40. 10.1186/1476-4598-10-40, 3100246, 21501485.
112. Rizzo S, et al. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther 2011, 10:325-335. 10.1158/1535-7163.MCT-10-0788, 3037846, 21216927.
113. Chatoo W, et al. The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 2009, 29:529-542. 2744209, 19144853.
114. Stupp R, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466. 10.1016/S1470-2045(09)70025-7, 19269895.
115. Li Z, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009, 15:501-513. 10.1016/j.ccr.2009.03.018, 2693960, 19477429.
116. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284. 10.4161/cc.8.20.9701, 2825672, 19770585.
117. Seidel S, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133:983-995. 10.1093/brain/awq042, 20375133.
118. Heddleston JM, et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential. Cell Death Differ 2012, 19:428-439. 10.1038/cdd.2011.109, 3229666,3229666, 21836617.
119. Cheng L, et al. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol 2007, 211:1-9. 10.1002/path.2105, 17117392.
120. Jones TD, Ulbright TM, Eble JN, Cheng L. OCT4: a sensitive and specific biomarker for intratubular germ cell neoplasia of the testis. Clin Cancer Res 2004, 10:8544-8547. 10.1158/1078-0432.CCR-04-0688, 15623637.
121. Jones TD, Ulbright TM, Eble JN, Baldridge LA, Cheng L. OCT4 staining in testicular tumors: a sensitive and specific marker for seminoma and embryonal carcinoma. Am J Surg Pathol 2004, 28:935-940. 10.1097/00000478-200407000-00014, 15223965.
122. Strickland S, Smith KK, Marotti KR. Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 1980, 21:347-355. 10.1016/0092-8674(80)90471-7, 6250719.
123. Wang J, et al. Novel histone demethylase LSD1 inhibitors selectively target cancer cells with pluripotent stem cell properties. Cancer Res 2011, 71:7238-7249. 10.1158/0008-5472.CAN-11-0896, 3228901, 21975933.